We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alexandria (ARE) Sees Demand, Seals Early Renewal With insitro
Read MoreHide Full Article
Alexandria Real Estate Equities, Inc. (ARE - Free Report) recently clinched an early renewal with the machine learning-powered drug discovery and development company insitro for a six-year lease extension at the Alexandria Center for Advanced Technologies mega campus in South San Francisco.
Being a significant early renewal, the lease extension for 143,188 rentable square feet (RSF) at 279 East Grand Avenue will run through Aug 31, 2034. This move will ensure steady rental revenues from this property for the long term.
It emphasizes the necessity for ample laboratory facilities to produce extensive datasets crucial for AI-driven advancements in medicine and reaffirms Alexandria's strong capacity to facilitate companies engaged in the burgeoning area of AI-enhanced laboratory-based research and development.
Acknowledging the potential of insitro's groundbreaking platform that leverages AI, particularly machine learning (ML), and extensive data to unravel complex biological processes and uncover novel medications across various therapeutic domains, including metabolism, oncology and neuroscience, Alexandria had executed its first lease with insitro in 2018. That lease encompassed nearly 36,000 RSF Labspace infrastructure at 279 East Grand Avenue.
The South San Francisco submarket is home to the densest concentration of life science companies in the San Francisco Bay Area. Alexandria made its entry into the South San Francisco submarket in 1998 and, over the years, has strategically expanded its footprint, which now comprises roughly 3.4 million RSF in operation (as of Dec 31, 2023).
Aggregating 1.0 million RSF of operating properties and future development opportunities as of Dec 31, 2023, Alexandria Center for Advanced Technologies – South San Francisco mega campus is positioned at the center of the submarket and is well-poised to cater to the needs of disruptive companies like insitro.
AI/ML holds vast potential to expedite and streamline the discovery and development of new medications, thereby reducing the time and cost associated with the entire research and development process.
Alexandria caters to a diversified tenant base comprising high-quality companies ranging from multinational pharmaceutical companies, public and private biotechnology companies, manufacturers of complex medicines and top-tier investment-grade companies and institutions as well as technology entities.
As of Dec 31, 2023, mega campuses accounted for 75% of annual rental revenues in effect, and investment-grade or publicly traded large-cap tenants accounted for 52% of the annual rental revenues in effect. The weighted average remaining lease term of all tenants is 7.4 years, increasing from 7 years at the end of the prior quarter. For Alexandria’s top 20 tenants, it is 9.6 years, increasing from 8.9 years as of the end of the prior quarter. This ensures steady rental revenues over the long term.
Over the past six months, shares of this Zacks Rank #3 (Hold) company have rallied 29.1%, outperforming its industry's upside of 19%.
The Zacks Consensus Estimate for HST’s 2024 FFO per share is pegged at $1.97, which suggests year-over-year growth of 2.6%.
The Zacks Consensus Estimate for IRM’s 2024 FFO per share stands at $4.42, which indicates an increase of 7.3% from the year-ago quarter.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Alexandria (ARE) Sees Demand, Seals Early Renewal With insitro
Alexandria Real Estate Equities, Inc. (ARE - Free Report) recently clinched an early renewal with the machine learning-powered drug discovery and development company insitro for a six-year lease extension at the Alexandria Center for Advanced Technologies mega campus in South San Francisco.
Being a significant early renewal, the lease extension for 143,188 rentable square feet (RSF) at 279 East Grand Avenue will run through Aug 31, 2034. This move will ensure steady rental revenues from this property for the long term.
It emphasizes the necessity for ample laboratory facilities to produce extensive datasets crucial for AI-driven advancements in medicine and reaffirms Alexandria's strong capacity to facilitate companies engaged in the burgeoning area of AI-enhanced laboratory-based research and development.
Acknowledging the potential of insitro's groundbreaking platform that leverages AI, particularly machine learning (ML), and extensive data to unravel complex biological processes and uncover novel medications across various therapeutic domains, including metabolism, oncology and neuroscience, Alexandria had executed its first lease with insitro in 2018. That lease encompassed nearly 36,000 RSF Labspace infrastructure at 279 East Grand Avenue.
The South San Francisco submarket is home to the densest concentration of life science companies in the San Francisco Bay Area. Alexandria made its entry into the South San Francisco submarket in 1998 and, over the years, has strategically expanded its footprint, which now comprises roughly 3.4 million RSF in operation (as of Dec 31, 2023).
Aggregating 1.0 million RSF of operating properties and future development opportunities as of Dec 31, 2023, Alexandria Center for Advanced Technologies – South San Francisco mega campus is positioned at the center of the submarket and is well-poised to cater to the needs of disruptive companies like insitro.
AI/ML holds vast potential to expedite and streamline the discovery and development of new medications, thereby reducing the time and cost associated with the entire research and development process.
Alexandria caters to a diversified tenant base comprising high-quality companies ranging from multinational pharmaceutical companies, public and private biotechnology companies, manufacturers of complex medicines and top-tier investment-grade companies and institutions as well as technology entities.
As of Dec 31, 2023, mega campuses accounted for 75% of annual rental revenues in effect, and investment-grade or publicly traded large-cap tenants accounted for 52% of the annual rental revenues in effect. The weighted average remaining lease term of all tenants is 7.4 years, increasing from 7 years at the end of the prior quarter. For Alexandria’s top 20 tenants, it is 9.6 years, increasing from 8.9 years as of the end of the prior quarter. This ensures steady rental revenues over the long term.
Over the past six months, shares of this Zacks Rank #3 (Hold) company have rallied 29.1%, outperforming its industry's upside of 19%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks from the broader REIT sector are Host Hotels & Resorts (HST - Free Report) and Iron Mountain (IRM - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for HST’s 2024 FFO per share is pegged at $1.97, which suggests year-over-year growth of 2.6%.
The Zacks Consensus Estimate for IRM’s 2024 FFO per share stands at $4.42, which indicates an increase of 7.3% from the year-ago quarter.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.